HALMY yields 0.63% · JNJ yields 2.14%● Live data
📍 JNJ pulled ahead of the other in Year 8
Combined, HALMY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HALMY + JNJ for your $10,000?
Halma plc, through its subsidiaries, provides technology solutions in the safety, health, and environmental markets. It operates through three segments: Safety, Environmental & Analysis, and Medical. The Safety segment provides fire detection, specialist fire suppression, elevator safety, security sensors, people and vehicle flow technologies, specialized interlocks that control critical processes safely, and explosion protection and corrosion monitoring systems. This segment serves elevator safety, fire suppression, people and vehicle flow, fire detection, pressure management, industrial access control, and safe storage and transfer markets. The Environmental & Analysis segment offers optical, optoelectronic, and spectral imaging systems; water, air and gases monitoring technologies; instruments that detect hazardous gases and analyses air quality; and systems for water analysis and treatment. It serves the optical analysis, water analysis and treatment, gas detection, and environmental monitoring markets. The Medical segment provides critical fluidic components used by medical diagnostics and original equipment manufacturers; laboratory devices and systems that provide information to understand patient health and enable providers to make decisions across the continuum of care; technologies and solutions to enable in-vitro diagnostic systems and life-science discoveries and development; and technologies that enable positive outcomes across clinical specialties. This segment serves the life sciences, health assessment, and therapeutic solutions market. The company was incorporated in 1894 and is headquartered in Amersham, the United Kingdom.
Full HALMY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.